Xenon Pharmaceuticals reported Phase 3 results showing azetukalner produced a 53.2% placebo‑adjusted reduction in focal onset seizure frequency at the 25 mg dose, exceeding prior expectations and the company’s mid‑stage readouts. Xenon said it plans an FDA submission in the third quarter, positioning the oral KV7 channel opener for rapid regulatory progression if the filing is accepted. The dataset also showed dose‑dependent tolerability: higher discontinuation at 25 mg versus 15 mg, making the lower dose potentially more commercially attractive, analysts wrote. William Blair and other sell‑side firms described the efficacy as materially better than typical pivotal outcomes for focal epilepsy and noted the drug’s oral dosing could drive adoption. One‑line technical note: azetukalner acts on neuronal KV7 potassium channels to stabilize excitability and reduce seizure occurrence. The strength of this Phase 3 readout will reshape competitive positioning and M&A interest in the epilepsy space.